Comparison of the efficacy and safety of the different doses of rivaroxaban in treatment of left ventricular apical thrombus
10.3760/cma.j.issn.1008-6706.2016.21.018
- VernacularTitle:不同剂量利伐沙班用于左心室心尖部血栓治疗的临床效果及安全性比较
- Author:
Gaofeng XU
- Publication Type:Journal Article
- Keywords:
Rivaroxaban;
Thrombosis;
Heart ventricles;
Treatment outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(21):3272-3275,3276
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety analysis on the different doses of rivaroxaban in treatment of left ventricular apical thrombus.Methods 87 patients with left ventricular apical thrombus were randomly divided into warfarin group (n =21 ),rivaroxaban 1 group (n =22),rivaroxaban 2 group (n =21 )and rivaroxaban 3 group(n =23).Patients in the warfarin group were given the doses of warfarin 2.5mg once daily,and the doses were adjusted according to INR.Patients in the rivaroxaban 1 group were given the doses of rivaroxaban 10mg once daily.Patients in the rivaroxaban 2 group were given the doses of rivaroxaban 20mg once daily.Patients in the rivaroxaban 3 group were given the doses of rivaroxaban 15mg twice daily for 21d,then followed by 20mg once daily. Patients in the four groups were followed up for 3 months.The percent reduction of D -dimmer at taking drug 3d,D -dimmer normal time,left ventricular apical thrombus disappearing time,the number of disappearance and INR compliance rate were recorded.The occurrences of thromboembolic events and bleeding events in the four groups were recorded. Results The percent reduction of D -dimmer at taking drug 3d in the rivaroxaban 1 group,rivaroxaban 2 group and rivaroxaban 3 group were higher than the warfarin group,and the rivaroxaban 3 group were higher than the rivaroxaban 1 group and rivaroxaban 2 group,the D -dimmer normal time and thrombus disappearing time in the rivaroxaban 1 group,rivaroxaban 2 group and rivaroxaban 3 group were lower than the warfarin group,and the rivaroxaban 3 group were lower than the rivaroxaban 1 group and rivaroxaban 2 group,the differences were statistically significant(F =8.443,19.319,35.475,all P <0.05).The numbers of INR compliance in the rivaroxaban 3 group were higher than those in the warfarin group,the differences were statistically significant[18cases(78.3%)vs.9cases(42.9%),χ2 =5.803,P <0.05].There was 1 case of patient appeared minor bleeding in each rivaroxaban 1 group and rivaroxaban 3 group.The occurrence rates of thromboembolic events and bleeding events in the rivaroxaban 1 group,rivaroxaban 2 group and rivaroxaban 3 group were lower than those in the warfarin group,but the differences were not statistically significant(χ2 =0.732,2.357,all P >0.05).Conclusion Rivaroxaban applied to treatment of left ventricular apical thrombus was safe and effective,and without increasing embolism and bleeding events.And treatment plan of the doses of rivaroxaban 15mg twice daily for 21d,then followed by 20mg once daily was superior.
